@article{Landew_R-2022_79654,
title = {EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.},
author = {Landewé, R. and Kroon, F. and Alunno, A. and Najm, A. and Bijlsma, J. and Burmester, G. and Caporali, R. and Combe, B. and Conway, R. and Curtis, J. and Elkayam, O. and Gossec, L. and Heijstek, M. and Haupt, L. and Iagnocco, A. and Isaacs, J. and Juhász, I. and Makri, S. and Mariette, X. and McInnes, I. and Mehta, P. and Mueller-Ladner, U. and Schulze-Koops, H. and Smolen, J. and Wiek, D. and Winthrop, K. and Navarro-Compán, V. and Machado, P.},
month = {feb},
year = {2022},
abstract = {The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway.},
journal = {Annals of the Rheumatic Diseases},
publisher = {BMJ Publishing Group},
url = {http://dx.doi.org/10.1136/annrheumdis-2021-222006},
}
